These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19853899)

  • 1. Trial design for evaluation of novel targeted therapies.
    Farley J; Rose PG
    Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?
    LoRusso PM; Anderson AB; Boerner SA; Averbuch SD
    Clin Cancer Res; 2010 Dec; 16(24):5956-62. PubMed ID: 21169248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternate endpoints for screening phase II studies.
    Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
    Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal two-stage randomized multinomial designs for Phase II oncology trials.
    Sun LZ; Chen C; Patel K
    J Biopharm Stat; 2009; 19(3):485-93. PubMed ID: 19384690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
    Ratain MJ; Karrison TG
    Clin Cancer Res; 2007 Feb; 13(3):781-2. PubMed ID: 17289865
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.